Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

This study has been completed.

Study NCT00052689 Information provided by National Cancer Institute (NCI)

First Received: January 24, 2003 Last Updated: July 23, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Alberts S, Gill S, Foster N, et al.: PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma (ACA): final results of a North Central Cancer Treatment Group (NCCTG) randomized phase II study. [Abstract] American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 27-29 January 2005, Miami, Florida. A-129, 2005.

Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol. 2005 Oct;16(10):1654-61. Epub 2005 Aug 5.